OXiGENE Inc (OXGN.OQ)
OXGN.OQ on NASDAQ Stock Exchange Capital Market
2.88USD
1 Aug 2013
2.88USD
1 Aug 2013
Price Change (% chg)
$0.07 (+2.49%)
$0.07 (+2.49%)
Prev Close
$2.81
$2.81
Open
$2.79
$2.79
Day's High
$2.88
$2.88
Day's Low
$2.79
$2.79
Volume
300
300
Avg. Vol
8,596
8,596
52-wk High
$9.36
$9.36
52-wk Low
$2.35
$2.35
About
OXiGENE, Inc. (OXiGENE) is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company’s primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that disable and destroy abnormal blood vessels that provide solid tumors a means of... (more)
No analyst recommendations are available for OXGN.OQ.
Overall
| Beta: | 1.86 |
| Market Cap (Mil.): | $6.37 |
| Shares Outstanding (Mil.): | 2.27 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| OXGN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -5.21 | -- | -- |
| ROI: | -135.97 | -2.58 | 18.76 |
| ROE: | -136.03 | -2.66 | 19.59 |
Competitors
| Price | Change | |
|---|---|---|
| Sanofi SA (SASY.PA) | €76.37 | -3.80 |
| MediciNova, Inc. (MNOV.OQ) | $2.60 | -0.08 |
| Myrexis Inc (MYRX.PK) | $0.07 | +0.00 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Merck & Co., Inc. (MRK.N) | $48.10 | -0.07 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

